Hjem › Tykktarmskreft › Tennessee › Nashville
Kliniske studier for Tykktarmskreft i Nashville, TN
16 studier for Tykktarmskreft søker deltakere på steder i og rundt Nashville (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of PHN-012 in Patients With Advanced Solid Tumors
RekruttererFase 1
- PHN-012-001 Site, Nashville
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RekruttererFase 3
- Henry-Joyce Cancer Clinic, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- Sarah Cannon Research Institue, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
RekruttererFase 1/2
- Tennessee Oncology, PLLC, Nashville
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
RekruttererFase 1/2
- GSK Investigational Site, Nashville
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
RekruttererFase 2/3
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruttererFase 1
- Xencor Investigative Site, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RekruttererFase 1
- Sarah Cannon, SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RekruttererFase 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
RekruttererFase 2
- SCRI Oncology Partners, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RekruttererFase 1
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RekruttererFase 1
- Sarah Cannon Research Institute, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RekruttererFase 1/2
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Sarah Cannon Research Institute, Nashville
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
RekruttererObservasjonsstudie
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Nashville
Tykktarmskreft-studier i andre byer
- Boston, MA22 studier
- New York City, NY22 studier
- Houston, TX20 studier
- Los Angeles, CA16 studier
- St. Louis, MO15 studier
- Arlington, VA15 studier
- Chicago, IL14 studier
- San Antonio, TX14 studier
- Baldwin Park, CA14 studier
- Baltimore, MD13 studier
- Tampa, FL13 studier
- Washington, DC12 studier
Andre studier i Nashville
- Ikke-småcellet lungekreft97 studier
- Brystkreft81 studier
- Metastatisk kreft70 studier
- Kolorektal kreft69 studier
- Kreft (alle typer)65 studier
- Eggstokkreft49 studier
- Prostatakreft43 studier
- Lungekreft40 studier
- Plateepitelcancer i hode og hals39 studier
- Pankreaskreft39 studier
- Endometriekreft38 studier
- Melanom33 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.